Mirum Pharmaceuticals Inc. (08D)
XFRA 
Summary
08D Chart
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum Pharmaceuticals Inc. (08D) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mirum Pharmaceuticals Inc. ever had a stock split?
Mirum Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Christopher Peetz CEO | XFRA Exchange | 604749101 CUSIP |
| US Country | 418 Employees | - Last Dividend | - Last Split | 18 Jul 2019 IPO Date |
Overview
Mirum Pharmaceuticals, Inc. is a pioneering biopharmaceutical company with a sharp focus on the discovery, development, and commercialization of innovative therapies designed to tackle debilitating rare and orphan diseases. Established in 2018 and based in Foster City, California, Mirum Pharmaceuticals has swiftly moved to the forefront of its field, aiming to deliver significant medical advancements for conditions with limited treatment options. The company's strategic approach combines breakthrough science with an unwavering commitment to improving patient outcomes, positioning it as a leader in rare disease therapy development.
Products and Services
- LIVMARLI (maralixibat)
This flagship product stands out as Mirum Pharmaceuticals' premier offering. LIVMARLI is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor. It has gained approval for the treatment of cholestatic pruritus in patients suffering from Alagille syndrome both in the United States and on an international scale. LIVMARLI's innovative mechanism offers new hope for patients grappling with this challenging and rare condition, illustrating the company's dedication to filling critical treatment gaps in rare diseases.
- Cholbam
A cholic acid capsule, Cholbam is another critical component of Mirum Pharmaceuticals' product lineup. The U.S. Food and Drug Administration (FDA) has approved it for use in both pediatric and adult patients who are dealing with bile acid synthesis disorders resulting from single enzyme defects. Furthermore, Cholbam is sanctioned as an adjunctive treatment for various peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome. This approval underscores the company's commitment to addressing unmet needs across a spectrum of rare bile acid disorders.
- Chenodal
Approved for the treatment of radiolucent stones in the gallbladder, Chenodal is a key drug in Mirum Pharmaceuticals' suite of products. Beyond its established use, Chenodal is currently under Phase 3 development for addressing cerebrotendinous xanthomatosis, showcasing the company's ongoing efforts to expand its impact across additional rare diseases through rigorous clinical development.
- Volixibat
Mirum Pharmaceuticals is also advancing Volixibat, a promising therapeutic under investigation. Like LIVMARLI, Volixibat is designed to inhibit the IBAT through an oral, minimally absorbed formulation. Currently in a Phase 2b clinical trial, Volixibat targets the treatment of adult patients with cholestatic liver diseases, signifying the company's continuous pursuit of innovative solutions for complex liver conditions.
